Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other 1

Conditions

Multiple Myeloma 251Neoplasms, Plasma Cell 91Lymphoma, Non-Hodgkin 33Hodgkin Disease 33Leukemia, Lymphocytic, Chronic, B-Cell 30Lymphoma 29Leukemia 29Immunoglobulin Light-chain Amyloidosis 29Myelodysplastic Syndromes 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia, Myeloid, Acute 25Lymphoma, Mantle-Cell 20Lymphoma, Follicular 20Myeloproliferative Disorders 19Lymphoma, Large B-Cell, Diffuse 19Lymphoma, B-Cell, Marginal Zone 19Recurrence 17Lymphoma, Large-Cell, Immunoblastic 17Burkitt Lymphoma 17Primary Myelofibrosis 14Congenital Abnormalities 14Anemia, Aplastic 13Waldenstrom Macroglobulinemia 12Leukemia, Myeloid, Chronic-Phase 12Leukemia, Myeloid, Accelerated Phase 12Leukemia, Myelomonocytic, Chronic 11Hematologic Neoplasms 11Graft vs Host Disease 11Dendritic Cell Sarcoma, Interdigitating 10Lymphoma, T-Cell, Cutaneous 9

Interventions

Melphalan 2Filgrastim 2Fibroblast Growth Factor 7 2Cyclophosphamide 2Amifostine 2sargramostim 1Sirolimus 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Ifosfamide 1Etoposide 1Epoetin Alfa 1Deoxycytidine 1Cytarabine 1Carboplatin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Melphalan × Plasma cell × Clear all
NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00482846 2014-04-15

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
38 enrolled
OtherPlasma cell

Multiple Myeloma, Mucositis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡